Yan Wu, Chen Danrong, Bigambo Francis Manyori, Wei Hongcheng, Wang Xu, Xia Yankai
State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, No.101 Longmian Road, Nanjing, Nanjing, 211166, China.
Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.
BMC Infect Dis. 2021 Feb 8;21(1):156. doi: 10.1186/s12879-021-05847-9.
Due to the rapid spread of coronavirus disease 2019 (COVID-19) worldwide, it is necessary to ascertain essential immune inflammatory parameters that describe the severity of the disease and provide guidance for treatment. We performed network meta-analyses to determine differences in blood cells, lymphocyte subsets, and cytokines in COVID-19 patients with different clinical stages.
Databases were systematically searched to May 2, 2020, and updated on June 1, 2020. Network meta-analyses were conducted via Stata 15.0, and the mean difference (MD) and its 95% CI were used as the effect values of the pooled analysis.
Seventy-one studies were included involving 8647 COVID-19 patients, White blood cell (WBC), neutrophil (NEUT), IL-6, and IL-10 counts increased significantly with worsening of the COVID-19, while lymphocyte (LYM) counts decreased. The levels of platelet (PLT), CD3, CD4, CD8, and CD19 cells in severe and critical patients were significantly lower than those in mild patients. IL-1β count was significantly elevated in critical patients.
Immune suppression and inflammatory injury play crucial roles in the progression of COVID-19, and the identification of susceptible cells and cytokines provide guidance for the early and accurate treatment of COVID-19 patients.
由于2019冠状病毒病(COVID-19)在全球迅速传播,有必要确定描述该疾病严重程度的关键免疫炎症参数,并为治疗提供指导。我们进行了网络荟萃分析,以确定不同临床阶段COVID-19患者血细胞、淋巴细胞亚群和细胞因子的差异。
系统检索数据库至2020年5月2日,并于2020年6月1日更新。通过Stata 15.0进行网络荟萃分析,合并分析的效应值采用平均差(MD)及其95%置信区间。
纳入71项研究,涉及8647例COVID-19患者。随着COVID-19病情加重,白细胞(WBC)、中性粒细胞(NEUT)、白细胞介素-6(IL-6)和白细胞介素-10(IL-10)计数显著增加,而淋巴细胞(LYM)计数减少。重症和危重症患者的血小板(PLT)、CD3、CD4、CD8和CD19细胞水平显著低于轻症患者。危重症患者白细胞介素-1β(IL-1β)计数显著升高。
免疫抑制和炎症损伤在COVID-19进展中起关键作用,识别易感细胞和细胞因子可为COVID-19患者的早期准确治疗提供指导。